Overview

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

Phase:

Phase 1

Details

Lead Sponsor:

Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.